The power of multisector partnerships in vaccine manufacturing

Harnessing momentum toward vaccine equity and pandemic preparedness

Jessica Milman, MPH
Global Head, Center for Vaccine Innovation and Access
Acting Chief of Essential Medicines
Our work happens through established, trusted relationships across sectors
Partner continuity builds on success

Trust, knowhow, and deep mutual understanding enables innovation, efficiency, and impact.

Example
Serum Institute of India, PATH, and others have advanced the development of affordable and accessible vaccines for over two decades, including conjugate vaccines.

- **MenAfriVac®** meningococcal meningitis A vaccine
- **Pneumosil®** 10-valent pneumococcal vaccine
- **MenFive®** pentavalent meningococcal meningitis vaccine

* = WHO prequalification
Diverse networks broaden potential

Visibility into potential collaborations and innovations not otherwise apparent—in and outside of pandemics.

Example
International, multisector relationships stemming from the 2009 influenza A/H1N1 pandemic were springboard for merging traditional egg-based vaccine production technology with cutting-edge science for COVID-19 vaccine development.

• Egg-based COVID-19 vaccine platform uses innovative Newcastle disease virus modified with stabilized spike protein.
• Can be sustainably made in low- and middle-income markets.
Technical assistance tips the balance toward progress

Transition past specific hurdles and on to the next milestone.

Example

- PATH provides tailored technical assistance across the entire vaccine development spectrum.
- In China, we provided support as Innovax readied its bivalent HPV vaccine, Cecolin, for WHO prequalification.

Cecolin WHO prequalified in 2021
Thank you!

For more information contact:

Jessica Milman
jmilman@path.org